. Author manuscript; available in PMC: 2015 Jun 15.

Published in final edited form as: Cancer. 2014 Mar 13;120(12):1780–1786. doi: 10.1002/cncr.28648

TABLE 2.

Patient Characteristics (N = 264)

Characteristics	Group 1: Bevacizumab	Group 2: No Bevacizumab	P
No. (%)	167	97
Median age (range), y	60 (31-85)	58 (33-78)	.17
Sex			.96
Male	78 (47)	47 (48)
Female	88 (53)	50 (52)
ECOG performance status
0	72 (43)	43 (44)	.64
1	92 (55)	47 (48)
0 or 1 (not specified)	3 (2)	7 (8)
Stage
IV	136 (100)	97 (100)	1.00
CA 19-9 ≥2× ULN
Yes	122 (73)	76 (78)	.46
No	44 (26)	21 (22)
Not available	1 (1)	0 (0)
Baseline albumin, g/dL
≥3.4	132 (75)	81 (83)	.15
<3.4	35 (25)	16(17)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of normal.